Skip to main content

Table 7 The infectivity of AE-Env clones containing D185 and the derived mutants

From: Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site

 

Relative infectivity (RLU)a

 

Mutation(s)b

Env clone

Wild-type

N186Q

N197Q

N186Q/N197Q

D185G/N186Q

D185G/N197Q

D185N/N197Q

D185E/N197Q

D185G/N186Q/N197Q

29CC1

573

587

773

704

 

708

371

364

662

45PB1

253

363

132

1

    

0

45CC1

464

780

302

357

 

243

167

194

68

47PL1

531

 

66

  

133

165

169

 

99PB2

188

 

79

  

129

   

99CC8

472

 

284

  

63

   

105PB1

293

94

64

106

 

55

67

26

27

105PL2

581

 

640

  

397

   

105PL3

355

128

146

39

 

108

83

31

26

107CC2

235

48

0

0

43

    
  1. aInfectivity of Env-recombinant virus was evaluated using U87.CD4.CXCR4 and U87.CD4.CCR5 cells. Relative infectivity of the virus was calculated by comparing it with the luciferase activity of pNL-envCT (pNL4-3)-infected U87.CD4.CXCR4 cells, which was defined as 100 relative light units (RLU).
  2. bSingle or multiple amino acid mutations were introduced into AE-Env-recombinant viruses. Amino acid numbering is based on HXB2 Env gp120.